New drug candidate LEO 158968 put to the test in healthy volunteers
NCT ID NCT05682352
First seen Apr 29, 2026 · Last updated Jun 19, 2026 · Updated 13 times
Summary
This early-stage trial tested a new compound called LEO 158968 in 120 healthy adults aged 18 to 60. The main goal was to check for side effects and see how well the drug is tolerated, as well as how it moves through and leaves the body. Participants received either the drug or a placebo in increasing doses. This study does not aim to treat any disease, but to gather important safety information for future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
LEO Pharma Investigational Site
Groningen, 9728, Netherlands
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.